Shanxi Zhendong Pilot Biotechnology

Zhendong Pilot Biotechnology is the dedicated innovative drug research and development subsidiary of the Shanxi Zhendong Pharmaceutical Group. The company focuses on the discovery and clinical development of small molecule targeted therapies, with a primary emphasis on oncology. Its lead candidate, ZD03, is a selective CDK4/6 inhibitor currently in Phase 2 clinical trials for the treatment of advanced breast cancer. By leveraging the extensive manufacturing infrastructure and commercial network of its parent group, Zhendong Pilot aims to modernize traditional therapeutic approaches and bring novel cancer treatments to the Chinese and global markets. The company is headquartered in the Shanxi Comprehensive Reform Demonstration Zone in Taiyuan, China.